Roivant Sciences Ltd. is an American multinational healthcare company focused on applying technology to drug development and building subsidiary life sciences and health technology companies. From Wikipedia
The TYK2/JAK1 pill delivered steroid-sparing benefits that underpin a planned early‑2026 FDA submission.
